165 related articles for article (PubMed ID: 33896649)
1. Immunity reloaded: Deconstruction of the PD-1 axis in B cell lymphomas.
Bednarska K; Nath K; Nicol W; Gandhi MK
Blood Rev; 2021 Nov; 50():100832. PubMed ID: 33896649
[TBL] [Abstract][Full Text] [Related]
2. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
3. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
4. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
5. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas.
Xu-Monette ZY; Zhou J; Young KH
Blood; 2018 Jan; 131(1):68-83. PubMed ID: 29118007
[TBL] [Abstract][Full Text] [Related]
6. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies.
Chen BJ; Chapuy B; Ouyang J; Sun HH; Roemer MG; Xu ML; Yu H; Fletcher CD; Freeman GJ; Shipp MA; Rodig SJ
Clin Cancer Res; 2013 Jul; 19(13):3462-73. PubMed ID: 23674495
[TBL] [Abstract][Full Text] [Related]
7. J chain and myocyte enhancer factor 2B are useful in differentiating classical Hodgkin lymphoma from nodular lymphocyte predominant Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.
Moore EM; Swerdlow SH; Gibson SE
Hum Pathol; 2017 Oct; 68():47-53. PubMed ID: 28851661
[TBL] [Abstract][Full Text] [Related]
8. Dendritic Cell Markers and PD-L1 are Expressed in Mediastinal Gray Zone Lymphoma.
Pelland K; Mathews S; Kamath A; Cohen P; Hudnall SD; Cotta CV; Xu ML
Appl Immunohistochem Mol Morphol; 2018; 26(10):e101-e106. PubMed ID: 29189264
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
10. Gray zone lymphoma: better treated like hodgkin lymphoma or mediastinal large B-cell lymphoma?
Dunleavy K; Grant C; Eberle FC; Pittaluga S; Jaffe ES; Wilson WH
Curr Hematol Malig Rep; 2012 Sep; 7(3):241-7. PubMed ID: 22833351
[TBL] [Abstract][Full Text] [Related]
11. Diagnostic utility of programmed cell death ligand 1 (clone SP142) in mediastinal composite lymphoma: A report of two cases.
Sakakibara A; Kohno K; Iwakoshi A; Moritani S; Fujishiro A; Kito K; Suzuki Y; Shimada S; Nakaguro M; Shimoyama Y; Takahara T; Takahashi E; Ohashi A; Satou A; Kato S; Asano N; Nakamura S
Pathol Int; 2020 Feb; 70(2):116-122. PubMed ID: 31894883
[TBL] [Abstract][Full Text] [Related]
12. Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade.
Chapuy B; Stewart C; Dunford AJ; Kim J; Wienand K; Kamburov A; Griffin GK; Chen PH; Lako A; Redd RA; Cote CM; Ducar MD; Thorner AR; Rodig SJ; Getz G; Shipp MA
Blood; 2019 Dec; 134(26):2369-2382. PubMed ID: 31697821
[TBL] [Abstract][Full Text] [Related]
13. Expression of programmed cell death 1 ligand 2 (PD-L2) is a distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2 copy gain.
Shi M; Roemer MG; Chapuy B; Liao X; Sun H; Pinkus GS; Shipp MA; Freeman GJ; Rodig SJ
Am J Surg Pathol; 2014 Dec; 38(12):1715-23. PubMed ID: 25025450
[TBL] [Abstract][Full Text] [Related]
14. Primary mediastinal large B-cell lymphoma, classic Hodgkin lymphoma presenting in the mediastinum, and mediastinal gray zone lymphoma: what is the oncologist to do?
Grant C; Dunleavy K; Eberle FC; Pittaluga S; Wilson WH; Jaffe ES
Curr Hematol Malig Rep; 2011 Sep; 6(3):157-63. PubMed ID: 21590365
[TBL] [Abstract][Full Text] [Related]
15. The utility of CD83, fascin and CD23 in the differential diagnosis of primary mediastinal large B-cell lymphoma versus classic Hodgkin lymphoma.
Aladily TN; Mansour A; Alsughayer A; Sughayer M; Medeiros LJ
Ann Diagn Pathol; 2019 Jun; 40():72-76. PubMed ID: 31075666
[TBL] [Abstract][Full Text] [Related]
16. PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Tang G; Fan G; Xu J
Biomedicines; 2022 Jul; 10(7):. PubMed ID: 35884893
[TBL] [Abstract][Full Text] [Related]
17. Identifying and treating candidates for checkpoint inhibitor therapies in multiple myeloma and lymphoma.
Hradska K; Kascak M; Hajek R; Jelinek T
Expert Rev Hematol; 2020 Apr; 13(4):375-392. PubMed ID: 32116068
[No Abstract] [Full Text] [Related]
18. PD-L1 Status in Refractory Lymphomas.
Vranic S; Ghosh N; Kimbrough J; Bilalovic N; Bender R; Arguello D; Veloso Y; Dizdarevic A; Gatalica Z
PLoS One; 2016; 11(11):e0166266. PubMed ID: 27861596
[TBL] [Abstract][Full Text] [Related]
19. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma.
Rosenwald A; Wright G; Leroy K; Yu X; Gaulard P; Gascoyne RD; Chan WC; Zhao T; Haioun C; Greiner TC; Weisenburger DD; Lynch JC; Vose J; Armitage JO; Smeland EB; Kvaloy S; Holte H; Delabie J; Campo E; Montserrat E; Lopez-Guillermo A; Ott G; Muller-Hermelink HK; Connors JM; Braziel R; Grogan TM; Fisher RI; Miller TP; LeBlanc M; Chiorazzi M; Zhao H; Yang L; Powell J; Wilson WH; Jaffe ES; Simon R; Klausner RD; Staudt LM
J Exp Med; 2003 Sep; 198(6):851-62. PubMed ID: 12975453
[TBL] [Abstract][Full Text] [Related]
20. Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma.
Carbone A; Gloghini A; Carlo-Stella C
Blood; 2023 May; 141(18):2187-2193. PubMed ID: 36898085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
